Currently, CRC treatment primarily relies on surgical resection and oxaliplatin-based chemotherapy, with targeted therapies limited to anti-VEGF (bevacizumab) and anti-EGFR (cetuximab) antibodies 47-49. Here, VEGFA is linked to colorectal carcinoma.